"ID   BRAF_HUMAN              Reviewed;         766 AA.\nAC   P15056; A4D1T4; B6HY61; B6HY62; B6HY63; B6HY64; B6HY65; B6HY66;\nAC   Q13878; Q3MIN6; Q9UDP8; Q9Y6T3;\nDT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.\nDT   19-JUL-2004, sequence version 4.\nDT   09-JUL-2014, entry version 183.\nDE   RecName: Full=Serine/threonine-protein kinase B-raf;\nDE            EC=2.7.11.1;\nDE   AltName: Full=Proto-oncogene B-Raf;\nDE   AltName: Full=p94;\nDE   AltName: Full=v-Raf murine sarcoma viral oncogene homolog B1;\nGN   Name=BRAF; Synonyms=BRAF1, RAFB1;\nOS   Homo sapiens (Human).\nOC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;\nOC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;\nOC   Catarrhini; Hominidae; Homo.\nOX   NCBI_TaxID=9606;\nRN   [1]\nRP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND\nRP   PHOSPHORYLATION AT THR-373.\nRC   TISSUE=Testis;\nRX   PubMed=1508179;\nRA   Stephens R.M., Sithanandam G., Copeland T.D., Kaplan D.R., Rapp U.R.,\nRA   Morrison D.K.;\nRT   \"95-kilodalton B-Raf serine/threonine kinase: identification of the\nRT   protein and its major autophosphorylation site.\";\nRL   Mol. Cell. Biol. 12:3733-3742(1992).\nRN   [2]\nRP   SEQUENCE REVISION TO 31-33.\nRA   Albert S., Wixler L., Rapp U.R.;\nRL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.\nRN   [3]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].\nRG   NIEHS SNPs program;\nRL   Submitted (MAR-2008) to the EMBL/GenBank/DDBJ databases.\nRN   [4]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].\nRX   PubMed=12690205; DOI=10.1126/science.1083423;\nRA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,\nRA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,\nRA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,\nRA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,\nRA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,\nRA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,\nRA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,\nRA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,\nRA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,\nRA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,\nRA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,\nRA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,\nRA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,\nRA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,\nRA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,\nRA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,\nRA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,\nRA   Mural R.J., Adams M.D., Tsui L.-C.;\nRT   \"Human chromosome 7: DNA sequence and biology.\";\nRL   Science 300:767-772(2003).\nRN   [5]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].\nRX   PubMed=12853948; DOI=10.1038/nature01782;\nRA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,\nRA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,\nRA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,\nRA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,\nRA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,\nRA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,\nRA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,\nRA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,\nRA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,\nRA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,\nRA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,\nRA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,\nRA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,\nRA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,\nRA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,\nRA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,\nRA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,\nRA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,\nRA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,\nRA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,\nRA   Waterston R.H., Wilson R.K.;\nRT   \"The DNA sequence of human chromosome 7.\";\nRL   Nature 424:157-164(2003).\nRN   [6]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].\nRC   TISSUE=Liver;\nRX   PubMed=15489334; DOI=10.1101/gr.2596504;\nRG   The MGC Project Team;\nRT   \"The status, quality, and expansion of the NIH full-length cDNA\nRT   project: the Mammalian Gene Collection (MGC).\";\nRL   Genome Res. 14:2121-2127(2004).\nRN   [7]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-200.\nRC   TISSUE=Placenta;\nRX   PubMed=1630826;\nRA   Eychene A., Barnier J.V., Apiou F., Dutrillaux B., Calothy G.;\nRT   \"Chromosomal assignment of two human B-raf(Rmil) proto-oncogene loci:\nRT   B-raf-1 encoding the p94Braf/Rmil and B-raf-2, a processed\nRT   pseudogene.\";\nRL   Oncogene 7:1657-1660(1992).\nRN   [8]\nRP   PROTEIN SEQUENCE OF 2-51; 56-95; 151-158; 189-199; 253-260; 294-354;\nRP   361-424; 444-507; 510-522; 559-570; 579-626; 663-680; 692-698;\nRP   702-719; 727-735 AND 753-766, CLEAVAGE OF INITIATOR METHIONINE,\nRP   ACETYLATION AT ALA-2, PHOSPHORYLATION AT SER-365; THR-396; SER-399;\nRP   THR-401 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY.\nRC   TISSUE=Colon carcinoma, and Hepatoma;\nRA   Bienvenut W.V., Boldt K., von Kriegsheim A.F., Zebisch A., Kolch W.;\nRL   Submitted (DEC-2008) to UniProtKB.\nRN   [9]\nRP   NUCLEOTIDE SEQUENCE [MRNA] OF 117-766.\nRC   TISSUE=Testis;\nRX   PubMed=2284096;\nRA   Sithanandam G., Kolch W., Duh F.-M., Rapp U.R.;\nRT   \"Complete coding sequence of a human B-raf cDNA and detection of B-raf\nRT   protein kinase with isozyme specific antibodies.\";\nRL   Oncogene 5:1775-1780(1990).\nRN   [10]\nRP   NUCLEOTIDE SEQUENCE [MRNA] OF 381-766, DISEASE, AND CHROMOSOMAL\nRP   REARRANGEMENT.\nRC   TISSUE=Brain;\nRX   PubMed=18974108; DOI=10.1158/0008-5472.CAN-08-2097;\nRA   Jones D.T.W., Kocialkowski S., Liu L., Pearson D.M., Backlund L.M.,\nRA   Ichimura K., Collins V.P.;\nRT   \"Tandem duplication producing a novel oncogenic BRAF fusion gene\nRT   defines the majority of pilocytic astrocytomas.\";\nRL   Cancer Res. 68:8673-8677(2008).\nRN   [11]\nRP   NUCLEOTIDE SEQUENCE [MRNA] OF 439-766.\nRX   PubMed=3043188;\nRA   Ikawa S., Fukui M., Ueyama Y., Tamaoki N., Yamamoto T., Toyoshima K.;\nRT   \"B-raf, a new member of the raf family, is activated by DNA\nRT   rearrangement.\";\nRL   Mol. Cell. Biol. 8:2651-2654(1988).\nRN   [12]\nRP   PHOSPHORYLATION AT SER-365 BY SGK1.\nRX   PubMed=11410590; DOI=10.1074/jbc.M102808200;\nRA   Zhang B.H., Tang E.D., Zhu T., Greenberg M.E., Vojtek A.B., Guan K.L.;\nRT   \"Serum- and glucocorticoid-inducible kinase SGK phosphorylates and\nRT   negatively regulates B-Raf.\";\nRL   J. Biol. Chem. 276:31620-31626(2001).\nRN   [13]\nRP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401, AND IDENTIFICATION\nRP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].\nRC   TISSUE=Cervix carcinoma;\nRX   PubMed=16964243; DOI=10.1038/nbt1240;\nRA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;\nRT   \"A probability-based approach for high-throughput protein\nRT   phosphorylation analysis and site localization.\";\nRL   Nat. Biotechnol. 24:1285-1292(2006).\nRN   [14]\nRP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].\nRC   TISSUE=Cervix carcinoma;\nRX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;\nRA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,\nRA   Greff Z., Keri G., Stemmann O., Mann M.;\nRT   \"Kinase-selective enrichment enables quantitative phosphoproteomics of\nRT   the kinome across the cell cycle.\";\nRL   Mol. Cell 31:438-448(2008).\nRN   [15]\nRP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-401; SER-446; SER-447\nRP   AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE\nRP   ANALYSIS].\nRC   TISSUE=Cervix carcinoma;\nRX   PubMed=18669648; DOI=10.1073/pnas.0805139105;\nRA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,\nRA   Elledge S.J., Gygi S.P.;\nRT   \"A quantitative atlas of mitotic phosphorylation.\";\nRL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).\nRN   [16]\nRP   SUBUNIT, INTERACTION WITH DGKH, AND PHOSPHORYLATION AT THR-753 BY\nRP   MAPK1.\nRX   PubMed=19710016; DOI=10.1074/jbc.M109.043604;\nRA   Yasuda S., Kai M., Imai S., Takeishi K., Taketomi A., Toyota M.,\nRA   Kanoh H., Sakane F.;\nRT   \"Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf\nRT   heterodimerization.\";\nRL   J. Biol. Chem. 284:29559-29570(2009).\nRN   [17]\nRP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].\nRC   TISSUE=Leukemic T-cell;\nRX   PubMed=19690332; DOI=10.1126/scisignal.2000007;\nRA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,\nRA   Rodionov V., Han D.K.;\nRT   \"Quantitative phosphoproteomic analysis of T cell receptor signaling\nRT   reveals system-wide modulation of protein-protein interactions.\";\nRL   Sci. Signal. 2:RA46-RA46(2009).\nRN   [18]\nRP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].\nRC   TISSUE=Cervix carcinoma;\nRX   PubMed=20068231; DOI=10.1126/scisignal.2000475;\nRA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,\nRA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,\nRA   Mann M.;\nRT   \"Quantitative phosphoproteomics reveals widespread full\nRT   phosphorylation site occupancy during mitosis.\";\nRL   Sci. Signal. 3:RA3-RA3(2010).\nRN   [19]\nRP   INTERACTION WITH KSR2, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION, AND\nRP   MUTAGENESIS OF LYS-483.\nRX   PubMed=21441910; DOI=10.1038/nature09860;\nRA   Brennan D.F., Dar A.C., Hertz N.T., Chao W.C., Burlingame A.L.,\nRA   Shokat K.M., Barford D.;\nRT   \"A Raf-induced allosteric transition of KSR stimulates phosphorylation\nRT   of MEK.\";\nRL   Nature 472:366-369(2011).\nRN   [20]\nRP   INTERACTION WITH PRMT5, METHYLATION AT ARG-671, CHARACTERIZATION OF\nRP   VARIANT CRC GLU-600, AND MUTAGENESIS OF ARG-671.\nRX   PubMed=21917714; DOI=10.1126/scisignal.2001936;\nRA   Andreu-Perez P., Esteve-Puig R., de Torre-Minguela C.,\nRA   Lopez-Fauqued M., Bech-Serra J.J., Tenbaum S., Garcia-Trevijano E.R.,\nRA   Canals F., Merlino G., Avila M.A., Recio J.A.;\nRT   \"Protein arginine methyltransferase 5 regulates ERK1/2 signal\nRT   transduction amplitude and cell fate through CRAF.\";\nRL   Sci. Signal. 4:RA58-RA58(2011).\nRN   [21]\nRP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION\nRP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].\nRX   PubMed=21406692; DOI=10.1126/scisignal.2001570;\nRA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,\nRA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,\nRA   Blagoev B.;\nRT   \"System-wide temporal characterization of the proteome and\nRT   phosphoproteome of human embryonic stem cell differentiation.\";\nRL   Sci. Signal. 4:RS3-RS3(2011).\nRN   [22]\nRP   UBIQUITINATION BY RNF149.\nRX   PubMed=22628551; DOI=10.1074/jbc.M111.319822;\nRA   Hong S.W., Jin D.H., Shin J.S., Moon J.H., Na Y.S., Jung K.A.,\nRA   Kim S.M., Kim J.C., Kim K.P., Hong Y.S., Lee J.L., Choi E.K.,\nRA   Lee J.S., Kim T.W.;\nRT   \"Ring finger protein 149 is an E3 ubiquitin ligase active on wild-type\nRT   v-Raf murine sarcoma viral oncogene homolog B1 (BRAF).\";\nRL   J. Biol. Chem. 287:24017-24025(2012).\nRN   [23]\nRP   UBIQUITINATION AT LYS-578, AND MUTAGENESIS OF LYS-578.\nRX   PubMed=23907581; DOI=10.1038/srep02344;\nRA   An L., Jia W., Yu Y., Zou N., Liang L., Zhao Y., Fan Y., Cheng J.,\nRA   Shi Z., Xu G., Li G., Yang J., Zhang H.;\nRT   \"Lys63-linked polyubiquitination of BRAF at lysine 578 is required for\nRT   BRAF-mediated signaling.\";\nRL   Sci. Rep. 3:2344-2344(2013).\nRN   [24]\nRP   X-RAY CRYSTALLOGRAPHY (2.57 ANGSTROMS) OF 444-719 IN COMPLEX WITH\nRP   INHIBITOR.\nRX   PubMed=18287029; DOI=10.1073/pnas.0711741105;\nRA   Tsai J., Lee J.T., Wang W., Zhang J., Cho H., Mamo S., Bremer R.,\nRA   Gillette S., Kong J., Haass N.K., Sproesser K., Li L., Smalley K.S.,\nRA   Fong D., Zhu Y.L., Marimuthu A., Nguyen H., Lam B., Liu J., Cheung I.,\nRA   Rice J., Suzuki Y., Luu C., Settachatgul C., Shellooe R., Cantwell J.,\nRA   Kim S.H., Schlessinger J., Zhang K.Y., West B.L., Powell B.,\nRA   Habets G., Zhang C., Ibrahim P.N., Hirth P., Artis D.R., Herlyn M.,\nRA   Bollag G.;\nRT   \"Discovery of a selective inhibitor of oncogenic B-Raf kinase with\nRT   potent antimelanoma activity.\";\nRL   Proc. Natl. Acad. Sci. U.S.A. 105:3041-3046(2008).\nRN   [25]\nRP   VARIANTS LNCR VAL-466 AND ARG-597.\nRX   PubMed=12460919;\nRA   Naoki K., Chen T.-H., Richards W.G., Sugarbaker D.J., Meyerson M.;\nRT   \"Missense mutations of the BRAF gene in human lung adenocarcinoma.\";\nRL   Cancer Res. 62:7001-7003(2002).\nRN   [26]\nRP   VARIANTS CANCER GLU-464; VAL-464; ALA-466; GLU-466; VAL-466; ALA-469;\nRP   GLU-469; LYS-586; LEU-595; ARG-596; ARG-597; VAL-597; GLU-600 AND\nRP   ASP-600, AND CHARACTERIZATION OF VARIANTS CANCER VAL-464; ALA-469;\nRP   VAL-597 AND GLU-600.\nRX   PubMed=12068308; DOI=10.1038/nature00766;\nRA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,\nRA   Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N.,\nRA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,\nRA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,\nRA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,\nRA   Shipley J., Hargrave D., Pritchard-Jones K., Maitland N.,\nRA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,\nRA   Flanagan A., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,\nRA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,\nRA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;\nRT   \"Mutations of the BRAF gene in human cancer.\";\nRL   Nature 417:949-954(2002).\nRN   [27]\nRP   VARIANTS CRC ILE-462; SER-463; GLU-464; GLU-600 AND GLU-601.\nRX   PubMed=12198537; DOI=10.1038/418934a;\nRA   Rajagopalan H., Bardelli A., Lengauer C., Kinzler K.W., Vogelstein B.,\nRA   Velculescu V.E.;\nRT   \"Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status.\";\nRL   Nature 418:934-934(2002).\nRN   [28]\nRP   VARIANTS NHL ALA-469; ARG-469 AND GLY-594.\nRX   PubMed=14612909; DOI=10.1038/sj.bjc.6601371;\nRA   Lee J.W., Yoo N.J., Soung Ark W.S., Kim S.Y., Lee J.H., Park J.Y.,\nRA   Cho Y.G., Kim C.J., Ko Y.H., Kim S.H., Nam S.W., Lee J.Y., Lee S.H.;\nRT   \"BRAF mutations in non-Hodgkin's lymphoma.\";\nRL   Br. J. Cancer 89:1958-1960(2003).\nRN   [29]\nRP   CHARACTERIZATION OF VARIANT MELANOMA GLU-600.\nRX   PubMed=14500344;\nRA   Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M.,\nRA   Tuveson D.A.;\nRT   \"Suppression of BRAF(V599E) in human melanoma abrogates\nRT   transformation.\";\nRL   Cancer Res. 63:5198-5202(2003).\nRN   [30]\nRP   VARIANTS CFC1 PRO-246; ARG-257; GLU-469; PHE-485; GLU-499; LYS-501;\nRP   GLY-501 AND ASP-581.\nRX   PubMed=16474404; DOI=10.1038/ng1749;\nRA   Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A.,\nRA   Okamoto N., Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D.,\nRA   Kavamura M.I., Kurosawa K., Ohashi H., Wilson L., Heron D.,\nRA   Bonneau D., Corona G., Kaname T., Naritomi K., Baumann C.,\nRA   Matsumoto N., Kato K., Kure S., Matsubara Y.;\nRT   \"Germline KRAS and BRAF mutations in cardio-facio-cutaneous\nRT   syndrome.\";\nRL   Nat. Genet. 38:294-296(2006).\nRN   [31]\nRP   VARIANT [LARGE SCALE ANALYSIS] GLU-600.\nRX   PubMed=16959974; DOI=10.1126/science.1133427;\nRA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,\nRA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,\nRA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,\nRA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,\nRA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,\nRA   Vogelstein B., Kinzler K.W., Velculescu V.E.;\nRT   \"The consensus coding sequences of human breast and colorectal\nRT   cancers.\";\nRL   Science 314:268-274(2006).\nRN   [32]\nRP   VARIANTS CFC1 ARG-257; ALA-467; SER-468; GLU-469; PHE-485; GLU-499;\nRP   LYS-501; GLY-501; ASP-581; LEU-595 AND VAL-596.\nRX   PubMed=16439621; DOI=10.1126/science.1124642;\nRA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,\nRA   Cruz M.S., McCormick F., Rauen K.A.;\nRT   \"Germline mutations in genes within the MAPK pathway cause cardio-\nRT   facio-cutaneous syndrome.\";\nRL   Science 311:1287-1290(2006).\nRN   [33]\nRP   VARIANTS [LARGE SCALE ANALYSIS] SER-301; ALA-469; VAL-469; SER-581;\nRP   ARG-596; ARG-597; VAL-597; GLU-600; GLU-600 AND GLU-600.\nRX   PubMed=17344846; DOI=10.1038/nature05610;\nRA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,\nRA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,\nRA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,\nRA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,\nRA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,\nRA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,\nRA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,\nRA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,\nRA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,\nRA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,\nRA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,\nRA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;\nRT   \"Patterns of somatic mutation in human cancer genomes.\";\nRL   Nature 446:153-158(2007).\nRN   [34]\nRP   VARIANTS CFC1 PRO-241; PRO-244; PRO-246; ARG-257; LYS-262; SER-468;\nRP   GLU-469; GLU-499; ASN-499; ASP-580; ASP-581 AND LEU-595.\nRX   PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x;\nRA   Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A.,\nRA   Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C.,\nRA   Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B.,\nRA   Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H.,\nRA   Spranger S., Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.;\nRT   \"Mutation and phenotypic spectrum in patients with cardio-facio-\nRT   cutaneous and Costello syndrome.\";\nRL   Clin. Genet. 73:62-70(2008).\nRN   [35]\nRP   VARIANT LEOPARD3 PRO-241, VARIANTS NS7 CYS-531 AND VAL-597, VARIANTS\nRP   CFC1 PHE-245; PRO-246; ARG-257; LYS-275; GLU-469; PHE-485; ASN-499;\nRP   LYS-501; PRO-525; LEU-595; ARG-599; GLN-601; GLU-638 AND ARG-709, AND\nRP   VARIANTS ARG-241 AND MET-241.\nRX   PubMed=19206169; DOI=10.1002/humu.20955;\nRA   Sarkozy A., Carta C., Moretti S., Zampino G., Digilio M.C.,\nRA   Pantaleoni F., Scioletti A.P., Esposito G., Cordeddu V., Lepri F.,\nRA   Petrangeli V., Dentici M.L., Mancini G.M., Selicorni A., Rossi C.,\nRA   Mazzanti L., Marino B., Ferrero G.B., Silengo M.C., Memo L.,\nRA   Stanzial F., Faravelli F., Stuppia L., Puxeddu E., Gelb B.D.,\nRA   Dallapiccola B., Tartaglia M.;\nRT   \"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous\nRT   syndromes: molecular diversity and associated phenotypic spectrum.\";\nRL   Hum. Mutat. 30:695-702(2009).\nRN   [36]\nRP   VARIANT CRC GLU-600.\nRX   PubMed=23263490; DOI=10.1038/ng.2503;\nRG   CORGI Consortium;\nRG   WGS500 Consortium;\nRA   Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M.,\nRA   Broderick P., Kemp Z., Spain S.L., Guarino Almeida E., Salguero I.,\nRA   Sherborne A., Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K.,\nRA   Dobbins S., Barclay E., Gorman M., Martin L., Kovac M.B., Humphray S.,\nRA   Lucassen A., Holmes C.C., Bentley D., Donnelly P., Taylor J.,\nRA   Petridis C., Roylance R., Sawyer E.J., Kerr D.J., Clark S., Grimes J.,\nRA   Kearsey S.E., Thomas H.J., McVean G., Houlston R.S., Tomlinson I.;\nRT   \"Germline mutations affecting the proofreading domains of POLE and\nRT   POLD1 predispose to colorectal adenomas and carcinomas.\";\nRL   Nat. Genet. 45:136-144(2013).\nCC   -!- FUNCTION: Protein kinase involved in the transduction of mitogenic\nCC       signals from the cell membrane to the nucleus. May play a role in\nCC       the postsynaptic responses of hippocampal neuron. Phosphorylates\nCC       MAP2K1, and thereby contributes to the MAP kinase signal\nCC       transduction pathway.\nCC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.\nCC   -!- COFACTOR: Binds 2 zinc ions per subunit (By similarity).\nCC   -!- ENZYME REGULATION: Activity is increased by EGF and HGF.\nCC   -!- SUBUNIT: Monomer. Homodimer. Heterodimerizes with RAF1, and the\nCC       heterodimer possesses a highly increased kinase activity compared\nCC       to the respective homodimers or monomers. Heterodimerization is\nCC       mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2\nCC       activation can induce a negative feedback that promotes the\nCC       dissociation of the heterodimer by phosphorylating BRAF at Thr-\nCC       753. Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3\nCC       and RGS14. Interacts with RIT1. Interacts (via N-terminus) with\nCC       RGS14 (via RBD domains); the interaction mediates the formation of\nCC       a ternary complex with RAF1, a ternary complex inhibited by GNAI1\nCC       (By similarity). Interacts with DGKH. Interacts with PRMT5.\nCC       Interacts with KSR2.\nCC   -!- INTERACTION:\nCC       Self; NbExp=8; IntAct=EBI-365980, EBI-365980;\nCC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-365980, EBI-352572;\nCC       Q61097:Ksr1 (xeno); NbExp=3; IntAct=EBI-365980, EBI-1536336;\nCC       Q13233:MAP3K1; NbExp=2; IntAct=EBI-365980, EBI-49776;\nCC       P04049:RAF1; NbExp=39; IntAct=EBI-365980, EBI-365996;\nCC       Q99N57:Raf1 (xeno); NbExp=3; IntAct=EBI-365980, EBI-397757;\nCC       Q8CGE9:Rgs12 (xeno); NbExp=2; IntAct=EBI-365980, EBI-7340552;\nCC       Q15349:RPS6KA2; NbExp=2; IntAct=EBI-365980, EBI-1384149;\nCC       Q13114:TRAF3; NbExp=2; IntAct=EBI-365980, EBI-357631;\nCC       P31946:YWHAB; NbExp=3; IntAct=EBI-365980, EBI-359815;\nCC       P63104:YWHAZ; NbExp=3; IntAct=EBI-365980, EBI-347088;\nCC   -!- SUBCELLULAR LOCATION: Nucleus (By similarity). Cytoplasm. Cell\nCC       membrane (By similarity). Note=Colocalizes with RGS14 and RAF1 in\nCC       both the cytoplasm and membranes (By similarity).\nCC   -!- TISSUE SPECIFICITY: Brain and testis.\nCC   -!- PTM: Phosphorylation at Ser-365 by SGK1 inhibits its activity.\nCC   -!- PTM: Methylation at Arg-671 decreases stability and kinase\nCC       activity.\nCC   -!- PTM: Ubiquitinated by RNF149; which leads to proteasomal\nCC       degradation. Polyubiquitinated at Lys-578 in response to EGF.\nCC   -!- DISEASE: Note=Defects in BRAF are found in a wide range of\nCC       cancers.\nCC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease\nCC       characterized by malignant lesions arising from the inner wall of\nCC       the large intestine (the colon) and the rectum. Genetic\nCC       alterations are often associated with progression from\nCC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk\nCC       factors for cancer of the colon and rectum include colon polyps,\nCC       long-standing ulcerative colitis, and genetic family history.\nCC       Note=The disease may be caused by mutations affecting the gene\nCC       represented in this entry.\nCC   -!- DISEASE: Lung cancer (LNCR) [MIM:211980]: A common malignancy\nCC       affecting tissues of the lung. The most common form of lung cancer\nCC       is non-small cell lung cancer (NSCLC) that can be divided into 3\nCC       major histologic subtypes: squamous cell carcinoma,\nCC       adenocarcinoma, and large cell lung cancer. NSCLC is often\nCC       diagnosed at an advanced stage and has a poor prognosis. Note=The\nCC       gene represented in this entry is involved in disease\nCC       pathogenesis.\nCC   -!- DISEASE: Familial non-Hodgkin lymphoma (NHL) [MIM:605027]: Cancer\nCC       that starts in cells of the lymph system, which is part of the\nCC       body's immune system. NHLs can occur at any age and are often\nCC       marked by enlarged lymph nodes, fever and weight loss. Note=The\nCC       gene represented in this entry is involved in disease\nCC       pathogenesis.\nCC   -!- DISEASE: Cardiofaciocutaneous syndrome 1 (CFC1) [MIM:115150]: A\nCC       multiple congenital anomaly disorder characterized by a\nCC       distinctive facial appearance, heart defects and mental\nCC       retardation. Heart defects include pulmonic stenosis, atrial\nCC       septal defects and hypertrophic cardiomyopathy. Some affected\nCC       individuals present with ectodermal abnormalities such as sparse,\nCC       friable hair, hyperkeratotic skin lesions and a generalized\nCC       ichthyosis-like condition. Typical facial features are similar to\nCC       Noonan syndrome. They include high forehead with bitemporal\nCC       constriction, hypoplastic supraorbital ridges, downslanting\nCC       palpebral fissures, a depressed nasal bridge, and posteriorly\nCC       angulated ears with prominent helices. Note=The disease is caused\nCC       by mutations affecting the gene represented in this entry.\nCC   -!- DISEASE: Noonan syndrome 7 (NS7) [MIM:613706]: A form of Noonan\nCC       syndrome, a disease characterized by short stature, facial\nCC       dysmorphic features such as hypertelorism, a downward eyeslant and\nCC       low-set posteriorly rotated ears, and a high incidence of\nCC       congenital heart defects and hypertrophic cardiomyopathy. Other\nCC       features can include a short neck with webbing or redundancy of\nCC       skin, deafness, motor delay, variable intellectual deficits,\nCC       multiple skeletal defects, cryptorchidism, and bleeding diathesis.\nCC       Individuals with Noonan syndrome are at risk of juvenile\nCC       myelomonocytic leukemia, a myeloproliferative disorder\nCC       characterized by excessive production of myelomonocytic cells.\nCC       Note=The disease is caused by mutations affecting the gene\nCC       represented in this entry.\nCC   -!- DISEASE: LEOPARD syndrome 3 (LEOPARD3) [MIM:613707]: A disorder\nCC       characterized by lentigines, electrocardiographic conduction\nCC       abnormalities, ocular hypertelorism, pulmonic stenosis,\nCC       abnormalities of genitalia, retardation of growth, and\nCC       sensorineural deafness. Note=The disease is caused by mutations\nCC       affecting the gene represented in this entry.\nCC   -!- DISEASE: Note=A chromosomal aberration involving BRAF is found in\nCC       pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads\nCC       to the expression of a KIAA1549-BRAF fusion protein with a\nCC       constitutive kinase activity and inducing cell transformation.\nCC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr\nCC       protein kinase family. RAF subfamily.\nCC   -!- SIMILARITY: Contains 1 phorbol-ester/DAG-type zinc finger.\nCC   -!- SIMILARITY: Contains 1 protein kinase domain.\nCC   -!- SIMILARITY: Contains 1 RBD (Ras-binding) domain.\nCC   -!- SEQUENCE CAUTION:\nCC       Sequence=AAD43193.1; Type=Erroneous gene model prediction;\nCC       Sequence=CAQ43111.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;\nCC       Sequence=CAQ43112.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;\nCC       Sequence=CAQ43113.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;\nCC       Sequence=CAQ43114.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;\nCC       Sequence=CAQ43115.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;\nCC       Sequence=CAQ43116.1; Type=Erroneous initiation; Note=Translation N-terminally shortened;\nCC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology\nCC       and Haematology;\nCC       URL=\"http://atlasgeneticsoncology.org/Genes/BRAFID828.html\";\nCC   -----------------------------------------------------------------------\nCC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms\nCC   Distributed under the Creative Commons Attribution-NoDerivs License\nCC   -----------------------------------------------------------------------\nDR   EMBL; M95712; AAA35609.2; -; mRNA.\nDR   EMBL; AC006344; AAD43193.1; ALT_SEQ; Genomic_DNA.\nDR   EMBL; EU600171; ACD11489.1; -; Genomic_DNA.\nDR   EMBL; AC006347; AAD15551.1; -; Genomic_DNA.\nDR   EMBL; CH236950; EAL24023.1; -; Genomic_DNA.\nDR   EMBL; BC101757; AAI01758.1; -; mRNA.\nDR   EMBL; BC112079; AAI12080.1; -; mRNA.\nDR   EMBL; X65187; CAA46301.1; -; Genomic_DNA.\nDR   EMBL; M21001; AAA96495.1; -; mRNA.\nDR   EMBL; AM989472; CAQ43111.1; ALT_INIT; mRNA.\nDR   EMBL; AM989473; CAQ43112.1; ALT_INIT; mRNA.\nDR   EMBL; AM989474; CAQ43113.1; ALT_INIT; mRNA.\nDR   EMBL; AM989475; CAQ43114.1; ALT_INIT; mRNA.\nDR   EMBL; AM989476; CAQ43115.1; ALT_INIT; mRNA.\nDR   EMBL; AM989477; CAQ43116.1; ALT_INIT; mRNA.\nDR   CCDS; CCDS5863.1; -.\nDR   PIR; A57977; TVHUBF.\nDR   RefSeq; NP_004324.2; NM_004333.4.\nDR   UniGene; Hs.550061; -.\nDR   UniGene; Hs.600998; -.\nDR   UniGene; Hs.605380; -.\nDR   UniGene; Hs.659507; -.\nDR   PDB; 1UWH; X-ray; 2.95 A; A/B=448-723.\nDR   PDB; 1UWJ; X-ray; 3.50 A; A/B=448-723.\nDR   PDB; 2FB8; X-ray; 2.90 A; A/B=445-723.\nDR   PDB; 2L05; NMR; -; A=149-232.\nDR   PDB; 3C4C; X-ray; 2.57 A; A/B=444-721.\nDR   PDB; 3D4Q; X-ray; 2.80 A; A/B=433-726.\nDR   PDB; 3IDP; X-ray; 2.70 A; A/B=434-727.\nDR   PDB; 3II5; X-ray; 2.79 A; A/B=432-726.\nDR   PDB; 3NY5; X-ray; 1.99 A; A/B/C/D=153-237.\nDR   PDB; 3OG7; X-ray; 2.45 A; A/B=449-766.\nDR   PDB; 3PPJ; X-ray; 3.70 A; A/B=432-726.\nDR   PDB; 3PPK; X-ray; 3.00 A; A/B=432-726.\nDR   PDB; 3PRF; X-ray; 2.90 A; A/B=432-726.\nDR   PDB; 3PRI; X-ray; 3.50 A; A/B=432-726.\nDR   PDB; 3PSB; X-ray; 3.40 A; A/B=433-726.\nDR   PDB; 3PSD; X-ray; 3.60 A; A/B=433-726.\nDR   PDB; 3Q4C; X-ray; 3.20 A; A/B=432-726.\nDR   PDB; 3Q96; X-ray; 3.10 A; A/B=446-727.\nDR   PDB; 3SKC; X-ray; 3.20 A; A/B=432-726.\nDR   PDB; 3TV4; X-ray; 3.40 A; A/B=432-726.\nDR   PDB; 3TV6; X-ray; 3.30 A; A/B=432-726.\nDR   PDB; 4DBN; X-ray; 3.15 A; A/B=445-726.\nDR   PDB; 4E26; X-ray; 2.55 A; A/B=432-726.\nDR   PDB; 4E4X; X-ray; 3.60 A; A/B=432-726.\nDR   PDB; 4EHE; X-ray; 3.30 A; A/B=432-726.\nDR   PDB; 4EHG; X-ray; 3.50 A; A/B=432-726.\nDR   PDB; 4FC0; X-ray; 2.95 A; A/B=445-726.\nDR   PDB; 4FK3; X-ray; 2.65 A; A/B=444-723.\nDR   PDB; 4G9C; X-ray; 3.50 A; A/B=432-726.\nDR   PDB; 4G9R; X-ray; 3.20 A; A/B=432-726.\nDR   PDB; 4H58; X-ray; 3.10 A; A/B/C=448-722.\nDR   PDB; 4JVG; X-ray; 3.09 A; A/B/C/D=444-723.\nDR   PDB; 4KSP; X-ray; 2.93 A; A/B=445-726.\nDR   PDB; 4KSQ; X-ray; 3.30 A; A/B=445-726.\nDR   PDB; 4MBJ; X-ray; 3.60 A; A/B=432-723.\nDR   PDB; 4PP7; X-ray; 3.40 A; A/B=432-726.\nDR   PDBsum; 1UWH; -.\nDR   PDBsum; 1UWJ; -.\nDR   PDBsum; 2FB8; -.\nDR   PDBsum; 2L05; -.\nDR   PDBsum; 3C4C; -.\nDR   PDBsum; 3D4Q; -.\nDR   PDBsum; 3IDP; -.\nDR   PDBsum; 3II5; -.\nDR   PDBsum; 3NY5; -.\nDR   PDBsum; 3OG7; -.\nDR   PDBsum; 3PPJ; -.\nDR   PDBsum; 3PPK; -.\nDR   PDBsum; 3PRF; -.\nDR   PDBsum; 3PRI; -.\nDR   PDBsum; 3PSB; -.\nDR   PDBsum; 3PSD; -.\nDR   PDBsum; 3Q4C; -.\nDR   PDBsum; 3Q96; -.\nDR   PDBsum; 3SKC; -.\nDR   PDBsum; 3TV4; -.\nDR   PDBsum; 3TV6; -.\nDR   PDBsum; 4DBN; -.\nDR   PDBsum; 4E26; -.\nDR   PDBsum; 4E4X; -.\nDR   PDBsum; 4EHE; -.\nDR   PDBsum; 4EHG; -.\nDR   PDBsum; 4FC0; -.\nDR   PDBsum; 4FK3; -.\nDR   PDBsum; 4G9C; -.\nDR   PDBsum; 4G9R; -.\nDR   PDBsum; 4H58; -.\nDR   PDBsum; 4JVG; -.\nDR   PDBsum; 4KSP; -.\nDR   PDBsum; 4KSQ; -.\nDR   PDBsum; 4MBJ; -.\nDR   PDBsum; 4PP7; -.\nDR   ProteinModelPortal; P15056; -.\nDR   SMR; P15056; 149-283, 448-723.\nDR   BioGrid; 107141; 41.\nDR   DIP; DIP-1045N; -.\nDR   IntAct; P15056; 36.\nDR   MINT; MINT-1574728; -.\nDR   STRING; 9606.ENSP00000288602; -.\nDR   BindingDB; P15056; -.\nDR   ChEMBL; CHEMBL5145; -.\nDR   DrugBank; DB00398; Sorafenib.\nDR   GuidetoPHARMACOLOGY; 1943; -.\nDR   PhosphoSite; P15056; -.\nDR   DMDM; 50403720; -.\nDR   MaxQB; P15056; -.\nDR   PaxDb; P15056; -.\nDR   PRIDE; P15056; -.\nDR   DNASU; 673; -.\nDR   Ensembl; ENST00000288602; ENSP00000288602; ENSG00000157764.\nDR   GeneID; 673; -.\nDR   KEGG; hsa:673; -.\nDR   UCSC; uc003vwc.4; human.\nDR   CTD; 673; -.\nDR   GeneCards; GC07M140424; -.\nDR   GeneReviews; BRAF; -.\nDR   H-InvDB; HIX0167822; -.\nDR   HGNC; HGNC:1097; BRAF.\nDR   HPA; CAB004552; -.\nDR   HPA; HPA001328; -.\nDR   MIM; 114500; phenotype.\nDR   MIM; 115150; phenotype.\nDR   MIM; 164757; gene.\nDR   MIM; 211980; phenotype.\nDR   MIM; 605027; phenotype.\nDR   MIM; 613706; phenotype.\nDR   MIM; 613707; phenotype.\nDR   neXtProt; NX_P15056; -.\nDR   Orphanet; 1340; Cardiofaciocutaneous syndrome.\nDR   Orphanet; 54595; Craniopharyngioma.\nDR   Orphanet; 58017; Hairy cell leukemia.\nDR   Orphanet; 99872; Hashimoto-Pritzker syndrome.\nDR   Orphanet; 500; LEOPARD syndrome.\nDR   Orphanet; 648; Noonan syndrome.\nDR   Orphanet; 251612; Pilocytic astrocytoma.\nDR   PharmGKB; PA25408; -.\nDR   eggNOG; COG0515; -.\nDR   HOVERGEN; HBG001886; -.\nDR   InParanoid; P15056; -.\nDR   KO; K04365; -.\nDR   OMA; HRTRTSS; -.\nDR   OrthoDB; EOG7F5128; -.\nDR   PhylomeDB; P15056; -.\nDR   TreeFam; TF317006; -.\nDR   BRENDA; 2.7.10.2; 2681.\nDR   Reactome; REACT_111102; Signal Transduction.\nDR   Reactome; REACT_116125; Disease.\nDR   Reactome; REACT_13685; Neuronal System.\nDR   SignaLink; P15056; -.\nDR   ChiTaRS; BRAF; human.\nDR   EvolutionaryTrace; P15056; -.\nDR   GeneWiki; BRAF_(gene); -.\nDR   GenomeRNAi; 673; -.\nDR   NextBio; 2776; -.\nDR   PMAP-CutDB; P15056; -.\nDR   PRO; PR:P15056; -.\nDR   ArrayExpress; P15056; -.\nDR   Bgee; P15056; -.\nDR   CleanEx; HS_BRAF; -.\nDR   Genevestigator; P15056; -.\nDR   GO; GO:0005829; C:cytosol; TAS:Reactome.\nDR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.\nDR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.\nDR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.\nDR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.\nDR   GO; GO:0005509; F:calcium ion binding; IDA:BHF-UCL.\nDR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.\nDR   GO; GO:0004709; F:MAP kinase kinase kinase activity; IEA:Ensembl.\nDR   GO; GO:0005515; F:protein binding; IPI:IntAct.\nDR   GO; GO:0004672; F:protein kinase activity; IDA:BHF-UCL.\nDR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.\nDR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.\nDR   GO; GO:0071277; P:cellular response to calcium ion; IDA:BHF-UCL.\nDR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.\nDR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.\nDR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0009887; P:organ morphogenesis; TAS:ProtInc.\nDR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.\nDR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.\nDR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.\nDR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.\nDR   GO; GO:0006468; P:protein phosphorylation; IDA:BHF-UCL.\nDR   GO; GO:0051591; P:response to cAMP; IEA:Ensembl.\nDR   GO; GO:0070849; P:response to epidermal growth factor; IDA:BHF-UCL.\nDR   GO; GO:0043434; P:response to peptide hormone; IEA:Ensembl.\nDR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.\nDR   GO; GO:0007268; P:synaptic transmission; TAS:Reactome.\nDR   InterPro; IPR020454; DAG/PE-bd.\nDR   InterPro; IPR011009; Kinase-like_dom.\nDR   InterPro; IPR002219; Prot_Kinase_C-like_PE/DAG-bd.\nDR   InterPro; IPR000719; Prot_kinase_dom.\nDR   InterPro; IPR017441; Protein_kinase_ATP_BS.\nDR   InterPro; IPR003116; Raf-like_ras-bd.\nDR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.\nDR   InterPro; IPR008271; Ser/Thr_kinase_AS.\nDR   InterPro; IPR029071; Ubiquitin-rel_dom.\nDR   Pfam; PF00130; C1_1; 1.\nDR   Pfam; PF07714; Pkinase_Tyr; 1.\nDR   Pfam; PF02196; RBD; 1.\nDR   PRINTS; PR00008; DAGPEDOMAIN.\nDR   SMART; SM00109; C1; 1.\nDR   SMART; SM00455; RBD; 1.\nDR   SUPFAM; SSF54236; SSF54236; 1.\nDR   SUPFAM; SSF56112; SSF56112; 1.\nDR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.\nDR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.\nDR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.\nDR   PROSITE; PS50898; RBD; 1.\nDR   PROSITE; PS00479; ZF_DAG_PE_1; 1.\nDR   PROSITE; PS50081; ZF_DAG_PE_2; 1.\nPE   1: Evidence at protein level;\nKW   3D-structure; Acetylation; ATP-binding; Cardiomyopathy; Cell membrane;\nKW   Chromosomal rearrangement; Complete proteome; Cytoplasm; Deafness;\nKW   Direct protein sequencing; Disease mutation; Ectodermal dysplasia;\nKW   Isopeptide bond; Kinase; Membrane; Mental retardation; Metal-binding;\nKW   Methylation; Nucleotide-binding; Nucleus; Phosphoprotein;\nKW   Polymorphism; Proto-oncogene; Reference proteome;\nKW   Serine/threonine-protein kinase; Transferase; Ubl conjugation; Zinc;\nKW   Zinc-finger.\nFT   INIT_MET      1      1       Removed.\nFT   CHAIN         2    766       Serine/threonine-protein kinase B-raf.\nFT                                /FTId=PRO_0000085665.\nFT   DOMAIN      155    227       RBD.\nFT   DOMAIN      457    717       Protein kinase.\nFT   ZN_FING     234    280       Phorbol-ester/DAG-type.\nFT   NP_BIND     463    471       ATP (By similarity).\nFT   COMPBIAS      6     11       Poly-Gly.\nFT   COMPBIAS    122    129       Poly-Ser.\nFT   COMPBIAS    428    432       Poly-Ser.\nFT   ACT_SITE    576    576       Proton acceptor (By similarity).\nFT   METAL       235    235       Zinc 1 (By similarity).\nFT   METAL       248    248       Zinc 2 (By similarity).\nFT   METAL       251    251       Zinc 2 (By similarity).\nFT   METAL       261    261       Zinc 1 (By similarity).\nFT   METAL       264    264       Zinc 1 (By similarity).\nFT   METAL       269    269       Zinc 2 (By similarity).\nFT   METAL       272    272       Zinc 2 (By similarity).\nFT   METAL       280    280       Zinc 1 (By similarity).\nFT   BINDING     483    483       ATP (By similarity).\nFT   SITE        380    381       Breakpoint for translocation to form\nFT                                KIAA1549-BRAF fusion protein.\nFT   SITE        438    439       Breakpoint for translocation to form\nFT                                KIAA1549-BRAF fusion protein.\nFT   MOD_RES       2      2       N-acetylalanine.\nFT   MOD_RES     365    365       Phosphoserine; by SGK1.\nFT   MOD_RES     373    373       Phosphothreonine; by autocatalysis.\nFT   MOD_RES     396    396       Phosphothreonine.\nFT   MOD_RES     399    399       Phosphoserine.\nFT   MOD_RES     401    401       Phosphothreonine.\nFT   MOD_RES     446    446       Phosphoserine.\nFT   MOD_RES     447    447       Phosphoserine.\nFT   MOD_RES     671    671       Omega-N-methylarginine; by PRMT5.\nFT   MOD_RES     729    729       Phosphoserine.\nFT   MOD_RES     753    753       Phosphothreonine; by MAPK1.\nFT   CROSSLNK    578    578       Glycyl lysine isopeptide (Lys-Gly)\nFT                                (interchain with G-Cter in ubiquitin).\nFT   VARIANT     241    241       T -> M (in a patient with Noonan\nFT                                syndrome).\nFT                                /FTId=VAR_058620.\nFT   VARIANT     241    241       T -> P (in CFC1 and LEOPARD3).\nFT                                /FTId=VAR_058621.\nFT   VARIANT     241    241       T -> R (in a patient with Noonan\nFT                                syndrome).\nFT                                /FTId=VAR_058622.\nFT   VARIANT     244    244       T -> P (in CFC1).\nFT                                /FTId=VAR_065171.\nFT   VARIANT     245    245       L -> F (in CFC1).\nFT                                /FTId=VAR_058623.\nFT   VARIANT     246    246       A -> P (in CFC1).\nFT                                /FTId=VAR_026113.\nFT   VARIANT     257    257       Q -> R (in CFC1).\nFT                                /FTId=VAR_026114.\nFT   VARIANT     262    262       Q -> K (in CFC1).\nFT                                /FTId=VAR_065172.\nFT   VARIANT     275    275       E -> K (in CFC1).\nFT                                /FTId=VAR_058624.\nFT   VARIANT     301    301       P -> S (in dbSNP:rs34776339).\nFT                                /FTId=VAR_040391.\nFT   VARIANT     462    462       R -> I (in CRC).\nFT                                /FTId=VAR_018613.\nFT   VARIANT     463    463       I -> S (in CRC).\nFT                                /FTId=VAR_018614.\nFT   VARIANT     464    464       G -> E (in CRC).\nFT                                /FTId=VAR_018615.\nFT   VARIANT     464    464       G -> V (in a colorectal cancer cell line;\nFT                                elevated kinase activity; efficiently\nFT                                induces cell transformation).\nFT                                /FTId=VAR_018616.\nFT   VARIANT     466    466       G -> A (in melanoma).\nFT                                /FTId=VAR_018617.\nFT   VARIANT     466    466       G -> E (in melanoma).\nFT                                /FTId=VAR_018618.\nFT   VARIANT     466    466       G -> V (in LNCR).\nFT                                /FTId=VAR_018512.\nFT   VARIANT     467    467       S -> A (in CFC1).\nFT                                /FTId=VAR_035096.\nFT   VARIANT     468    468       F -> S (in CFC1).\nFT                                /FTId=VAR_035097.\nFT   VARIANT     469    469       G -> A (in NHL; also in a lung\nFT                                adenocarcinoma sample; somatic mutation;\nFT                                elevated kinase activity; efficiently\nFT                                induces cell transformation).\nFT                                /FTId=VAR_018620.\nFT   VARIANT     469    469       G -> E (in CFC1 and colon cancer).\nFT                                /FTId=VAR_018621.\nFT   VARIANT     469    469       G -> R (in NHL).\nFT                                /FTId=VAR_018622.\nFT   VARIANT     469    469       G -> V (in a colorectal adenocarcinoma\nFT                                sample; somatic mutation).\nFT                                /FTId=VAR_040392.\nFT   VARIANT     485    485       L -> F (in CFC1).\nFT                                /FTId=VAR_026115.\nFT   VARIANT     499    499       K -> E (in CFC1).\nFT                                /FTId=VAR_026116.\nFT   VARIANT     499    499       K -> N (in CFC1).\nFT                                /FTId=VAR_058625.\nFT   VARIANT     501    501       E -> G (in CFC1).\nFT                                /FTId=VAR_026117.\nFT   VARIANT     501    501       E -> K (in CFC1).\nFT                                /FTId=VAR_026118.\nFT   VARIANT     525    525       L -> P (in CFC1).\nFT                                /FTId=VAR_058626.\nFT   VARIANT     531    531       W -> C (in NS7).\nFT                                /FTId=VAR_058627.\nFT   VARIANT     580    580       N -> D (in CFC1).\nFT                                /FTId=VAR_065173.\nFT   VARIANT     581    581       N -> D (in CFC1).\nFT                                /FTId=VAR_026119.\nFT   VARIANT     581    581       N -> S (in a colorectal adenocarcinoma\nFT                                sample; somatic mutation).\nFT                                /FTId=VAR_040393.\nFT   VARIANT     586    586       E -> K (in ovarian cancer).\nFT                                /FTId=VAR_018623.\nFT   VARIANT     594    594       D -> G (in NHL).\nFT                                /FTId=VAR_018624.\nFT   VARIANT     595    595       F -> L (in colon cancer and CFC1).\nFT                                /FTId=VAR_018625.\nFT   VARIANT     596    596       G -> R (in a colorectal adenocarcinoma\nFT                                sample; somatic mutation).\nFT                                /FTId=VAR_018626.\nFT   VARIANT     596    596       G -> V (in CFC1).\nFT                                /FTId=VAR_035098.\nFT   VARIANT     597    597       L -> R (in LNCR; also found in an ovarian\nFT                                serous carcinoma sample; somatic\nFT                                mutation).\nFT                                /FTId=VAR_018513.\nFT   VARIANT     597    597       L -> V (in NS7; also in a lung\nFT                                adenocarcinoma sample; somatic mutation;\nFT                                elevated kinase activity; efficiently\nFT                                induces cell transformation).\nFT                                /FTId=VAR_018627.\nFT   VARIANT     599    599       T -> R (in CFC1).\nFT                                /FTId=VAR_058628.\nFT   VARIANT     600    600       V -> D (in a melanoma cell line; requires\nFT                                2 nucleotide substitutions).\nFT                                /FTId=VAR_018628.\nFT   VARIANT     600    600       V -> E (in CRC; also found in sarcoma,\nFT                                metastatic melanoma, ovarian serous\nFT                                carcinoma, pilocytic astrocytoma; somatic\nFT                                mutation; most common mutation;\nFT                                constitutive and elevated kinase\nFT                                activity; efficiently induces cell\nFT                                transformation; suppression of mutation\nFT                                in melanoma causes growth arrest and\nFT                                promotes apoptosis; loss of regulation by\nFT                                PMRT5).\nFT                                /FTId=VAR_018629.\nFT   VARIANT     601    601       K -> E (in CRC).\nFT                                /FTId=VAR_018630.\nFT   VARIANT     601    601       K -> Q (in CFC1).\nFT                                /FTId=VAR_058629.\nFT   VARIANT     638    638       D -> E (in CFC1).\nFT                                /FTId=VAR_058630.\nFT   VARIANT     709    709       Q -> R (in CFC1).\nFT                                /FTId=VAR_058631.\nFT   MUTAGEN     483    483       K->S: Reduces kinase activity with\nFT                                MAP2K1.\nFT   MUTAGEN     578    578       K->R: Blocks EGF-induced ubiquitination\nFT                                and ERK activation.\nFT   MUTAGEN     671    671       R->K: Increased kinase activity and\nFT                                stability in response to EGF treatment.\nFT   CONFLICT    766    766       H -> D (in Ref. 11; AAA96495).\nFT   STRAND      156    161\nFT   TURN        162    164\nFT   STRAND      165    170\nFT   HELIX       177    186\nFT   TURN        187    189\nFT   HELIX       192    194\nFT   STRAND      195    199\nFT   STRAND      206    208\nFT   HELIX       214    217\nFT   STRAND      221    226\nFT   STRAND      458    465\nFT   STRAND      467    486\nFT   STRAND      487    489\nFT   HELIX       492    505\nFT   STRAND      516    520\nFT   STRAND      522    524\nFT   STRAND      526    530\nFT   STRAND      534    536\nFT   HELIX       537    541\nFT   TURN        542    544\nFT   HELIX       550    569\nFT   STRAND      581    585\nFT   TURN        586    588\nFT   STRAND      589    592\nFT   STRAND      599    601\nFT   HELIX       617    619\nFT   HELIX       622    625\nFT   STRAND      629    631\nFT   HELIX       635    651\nFT   TURN        655    658\nFT   HELIX       662    670\nFT   HELIX       678    680\nFT   STRAND      683    685\nFT   HELIX       687    696\nFT   HELIX       701    703\nFT   HELIX       707    716\nFT   HELIX       718    720\nSQ   SEQUENCE   766 AA;  84437 MW;  0798C2AAB487E813 CRC64;\n     MAALSGGGGG GAEPGQALFN GDMEPEAGAG AGAAASSAAD PAIPEEVWNI KQMIKLTQEH\n     IEALLDKFGG EHNPPSIYLE AYEEYTSKLD ALQQREQQLL ESLGNGTDFS VSSSASMDTV\n     TSSSSSSLSV LPSSLSVFQN PTDVARSNPK SPQKPIVRVF LPNKQRTVVP ARCGVTVRDS\n     LKKALMMRGL IPECCAVYRI QDGEKKPIGW DTDISWLTGE ELHVEVLENV PLTTHNFVRK\n     TFFTLAFCDF CRKLLFQGFR CQTCGYKFHQ RCSTEVPLMC VNYDQLDLLF VSKFFEHHPI\n     PQEEASLAET ALTSGSSPSA PASDSIGPQI LTSPSPSKSI PIPQPFRPAD EDHRNQFGQR\n     DRSSSAPNVH INTIEPVNID DLIRDQGFRG DGGSTTGLSA TPPASLPGSL TNVKALQKSP\n     GPQRERKSSS SSEDRNRMKT LGRRDSSDDW EIPDGQITVG QRIGSGSFGT VYKGKWHGDV\n     AVKMLNVTAP TPQQLQAFKN EVGVLRKTRH VNILLFMGYS TKPQLAIVTQ WCEGSSLYHH\n     LHIIETKFEM IKLIDIARQT AQGMDYLHAK SIIHRDLKSN NIFLHEDLTV KIGDFGLATV\n     KSRWSGSHQF EQLSGSILWM APEVIRMQDK NPYSFQSDVY AFGIVLYELM TGQLPYSNIN\n     NRDQIIFMVG RGYLSPDLSK VRSNCPKAMK RLMAECLKKK RDERPLFPQI LASIELLARS\n     LPKIHRSASE PSLNRAGFQT EDFSLYACAS PKTPIQAGGY GAFPVH\n//\nID   RASK_HUMAN              Reviewed;         189 AA.\nAC   P01116; A8K8Z5; B0LPF9; P01118; Q96D10;\nDT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.\nDT   21-JUL-1986, sequence version 1.\nDT   09-JUL-2014, entry version 178.\nDE   RecName: Full=GTPase KRas;\nDE   AltName: Full=K-Ras 2;\nDE   AltName: Full=Ki-Ras;\nDE   AltName: Full=c-K-ras;\nDE   AltName: Full=c-Ki-ras;\nDE   Contains:\nDE     RecName: Full=GTPase KRas, N-terminally processed;\nDE   Flags: Precursor;\nGN   Name=KRAS; Synonyms=KRAS2, RASK2;\nOS   Homo sapiens (Human).\nOC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;\nOC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;\nOC   Catarrhini; Hominidae; Homo.\nOX   NCBI_TaxID=9606;\nRN   [1]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B).\nRX   PubMed=6308466; DOI=10.1038/304501a0;\nRA   McGrath J.P., Capon D.J., Smith D.H., Chen E.Y., Seeburg P.H.,\nRA   Goeddel D.V., Levinson A.D.;\nRT   \"Structure and organization of the human Ki-ras proto-oncogene and a\nRT   related processed pseudogene.\";\nRL   Nature 304:501-506(1983).\nRN   [2]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B).\nRC   TISSUE=Lung carcinoma;\nRX   PubMed=6308465; DOI=10.1038/304497a0;\nRA   Shimizu K., Birnbaum D., Ruley M.A., Fasano O., Suard Y., Edlund L.,\nRA   Taparowsky E., Goldfarb M., Wigler M.;\nRT   \"Structure of the Ki-ras gene of the human lung carcinoma cell line\nRT   Calu-1.\";\nRL   Nature 304:497-500(1983).\nRN   [3]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B).\nRC   TISSUE=Colon carcinoma, and Lung;\nRX   PubMed=6308467; DOI=10.1038/304507a0;\nRA   Capon D.J., Seeburg P.H., McGrath J.P., Hayflick J.S., Edman U.,\nRA   Levinson A.D., Goeddel D.V.;\nRT   \"Activation of Ki-ras2 gene in human colon and lung carcinomas by two\nRT   different point mutations.\";\nRL   Nature 304:507-513(1983).\nRN   [4]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 2A AND 2B), AND VARIANT\nRP   COLON CANCER VAL-12.\nRC   TISSUE=Colon carcinoma;\nRX   PubMed=6092920;\nRA   McCoy M.S., Bargmann C.I., Weinberg R.A.;\nRT   \"Human colon carcinoma Ki-ras2 oncogene and its corresponding proto-\nRT   oncogene.\";\nRL   Mol. Cell. Biol. 4:1577-1582(1984).\nRN   [5]\nRP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2B).\nRX   PubMed=3310850;\nRA   Kahn S., Yamamoto F., Almoguera C., Winter E., Forrester K.,\nRA   Jordano J., Perucho M.;\nRT   \"The c-K-ras gene and human cancer (review).\";\nRL   Anticancer Res. 7:639-652(1987).\nRN   [6]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B).\nRC   TISSUE=Brain;\nRA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;\nRT   \"cDNA clones of human proteins involved in signal transduction\nRT   sequenced by the Guthrie cDNA resource center (www.cdna.org).\";\nRL   Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.\nRN   [7]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG\nRP   CARCINOMA HIS-61.\nRA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,\nRA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,\nRA   Phelan M., Farmer A.;\nRT   \"Cloning of human full-length CDSs in BD Creator(TM) system donor\nRT   vector.\";\nRL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.\nRN   [8]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B).\nRC   TISSUE=Testis;\nRX   PubMed=14702039; DOI=10.1038/ng1285;\nRA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,\nRA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,\nRA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,\nRA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,\nRA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,\nRA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,\nRA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,\nRA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,\nRA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,\nRA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,\nRA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,\nRA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,\nRA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,\nRA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,\nRA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,\nRA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,\nRA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,\nRA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,\nRA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,\nRA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,\nRA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,\nRA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,\nRA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,\nRA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,\nRA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,\nRA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,\nRA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,\nRA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;\nRT   \"Complete sequencing and characterization of 21,243 full-length human\nRT   cDNAs.\";\nRL   Nat. Genet. 36:40-45(2004).\nRN   [9]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].\nRG   SeattleSNPs variation discovery resource;\nRL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.\nRN   [10]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].\nRA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,\nRA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,\nRA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,\nRA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,\nRA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,\nRA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,\nRA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,\nRA   Venter J.C.;\nRL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.\nRN   [11]\nRP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2B), AND VARIANT LUNG\nRP   CARCINOMA HIS-61.\nRC   TISSUE=Lung carcinoma;\nRX   PubMed=15489334; DOI=10.1101/gr.2596504;\nRG   The MGC Project Team;\nRT   \"The status, quality, and expansion of the NIH full-length cDNA\nRT   project: the Mammalian Gene Collection (MGC).\";\nRL   Genome Res. 14:2121-2127(2004).\nRN   [12]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT LUNG CARCINOMA\nRP   CYS-12.\nRC   TISSUE=Lung carcinoma;\nRX   PubMed=6320174; DOI=10.1073/pnas.81.1.71;\nRA   Nakano H., Yamamoto F., Neville C., Evans D., Mizuno T., Perucho M.;\nRT   \"Isolation of transforming sequences of two human lung carcinomas:\nRT   structural and functional analysis of the activated c-K-ras\nRT   oncogenes.\";\nRL   Proc. Natl. Acad. Sci. U.S.A. 81:71-75(1984).\nRN   [13]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-96.\nRC   TISSUE=Pancreatic carcinoma;\nRX   PubMed=3855240; DOI=10.1016/S0006-291X(85)80140-6;\nRA   Hirai H., Okabe T., Anraku Y., Fujisawa M., Urabe A., Takaku F.;\nRT   \"Activation of the c-K-ras oncogene in a human pancreas carcinoma.\";\nRL   Biochem. Biophys. Res. Commun. 127:168-174(1985).\nRN   [14]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37, AND VARIANT GASC VAL-12.\nRX   PubMed=3034404;\nRA   Deng G., Lu Y., Chen S., Miao J., Lu G., Li H., Cai H., Xu X.,\nRA   Zheng E., Liu P.;\nRT   \"Activated c-Ha-ras oncogene with a guanine to thymine transversion at\nRT   the twelfth codon in a human stomach cancer cell line.\";\nRL   Cancer Res. 47:3195-3198(1987).\nRN   [15]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-36, AND VARIANT BLADDER/LUNG\nRP   CANCER ARG-12.\nRC   TISSUE=Lung carcinoma;\nRX   PubMed=6695174; DOI=10.1126/science.6695174;\nRA   Santos E., Martin-Zanca D., Reddy P.E., Pierotti M.A., Porta G.,\nRA   Barbacid M.;\nRT   \"Malignant activation of a K-ras oncogene in lung carcinoma but not in\nRT   normal tissue of the same patient.\";\nRL   Science 223:661-664(1984).\nRN   [16]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-37.\nRX   PubMed=3932274;\nRA   Sekiya T., Tokunaga A., Fushimi M.;\nRT   \"Essential region for transforming activity of human c-Ha-ras-1.\";\nRL   Jpn. J. Cancer Res. 76:787-791(1985).\nRN   [17]\nRP   PROTEIN SEQUENCE OF 1-41; 43-147 AND 150-161, CLEAVAGE OF INITIATOR\nRP   METHIONINE, ACETYLATION AT MET-1 AND THR-2, AND IDENTIFICATION BY MASS\nRP   SPECTROMETRY.\nRC   TISSUE=Cervix carcinoma;\nRA   Bienvenut W.V., Calvo F., Kolch W.;\nRL   Submitted (FEB-2008) to UniProtKB.\nRN   [18]\nRP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 38-96.\nRC   TISSUE=Lung carcinoma;\nRX   PubMed=6096811; DOI=10.1093/nar/12.23.8873;\nRA   Yamamoto F., Perucho M.;\nRT   \"Activation of a human c-K-ras oncogene.\";\nRL   Nucleic Acids Res. 12:8873-8885(1984).\nRN   [19]\nRP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].\nRX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;\nRA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,\nRA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;\nRT   \"Initial characterization of the human central proteome.\";\nRL   BMC Syst. Biol. 5:17-17(2011).\nRN   [20]\nRP   ACETYLATION AT LYS-104, AND VARIANT VAL-12.\nRX   PubMed=22711838; DOI=10.1073/pnas.1201487109;\nRA   Yang M.H., Nickerson S., Kim E.T., Liot C., Laurent G., Spang R.,\nRA   Philips M.R., Shan Y., Shaw D.E., Bar-Sagi D., Haigis M.C.,\nRA   Haigis K.M.;\nRT   \"Regulation of RAS oncogenicity by acetylation.\";\nRL   Proc. Natl. Acad. Sci. U.S.A. 109:10843-10848(2012).\nRN   [21]\nRP   VARIANT BREAST CANCER ASP-13.\nRX   PubMed=3627975; DOI=10.1093/nar/15.15.5963;\nRA   Kozma S.C., Bogaard M.E., Buser K., Saurer S.M., Bos J.L., Groner B.,\nRA   Hynes N.E.;\nRT   \"The human c-Kirsten ras gene is activated by a novel mutation in\nRT   codon 13 in the breast carcinoma cell line MDA-MB231.\";\nRL   Nucleic Acids Res. 15:5963-5971(1987).\nRN   [22]\nRP   VARIANT BLADDER CANCER THR-59.\nRX   PubMed=1553789; DOI=10.1007/BF00296523;\nRA   Grimmond S.M., Raghavan D., Russell P.J.;\nRT   \"Detection of a rare point mutation in Ki-ras of a human bladder\nRT   cancer xenograft by polymerase chain reaction and direct sequencing.\";\nRL   Urol. Res. 20:121-126(1992).\nRN   [23]\nRP   VARIANTS PANCREATIC CARCINOMA ASP-12 AND VAL-12.\nRX   PubMed=8439212; DOI=10.1097/00000658-199302000-00007;\nRA   Motojima K., Urano T., Nagata Y., Shiku H., Tsurifune T.,\nRA   Kanematsu T.;\nRT   \"Detection of point mutations in the Kirsten-ras oncogene provides\nRT   evidence for the multicentricity of pancreatic carcinoma.\";\nRL   Ann. Surg. 217:138-143(1993).\nRN   [24]\nRP   VARIANTS GASC SER-12 AND ASP-12.\nRX   PubMed=7773929;\nRX   DOI=10.1002/1097-0142(19950615)75:12<2794::AID-CNCR2820751203>3.0.CO;2-F;\nRA   Lee K.H., Lee J.S., Suh C., Kim S.W., Kim S.B., Lee J.H., Lee M.S.,\nRA   Park M.Y., Sun H.S., Kim S.H.;\nRT   \"Clinicopathologic significance of the K-ras gene codon 12 point\nRT   mutation in stomach cancer. An analysis of 140 cases.\";\nRL   Cancer 75:2794-2801(1995).\nRN   [25]\nRP   INVOLVEMENT IN AML, VARIANT GLY-10 INS, AND CHARACTERIZATION OF\nRP   VARIANT GLY-10 INS.\nRX   PubMed=8955068; DOI=10.1074/jbc.271.51.32491;\nRA   Bollag G., Adler F., elMasry N., McCabe P.C., Conner E. Jr.,\nRA   Thompson P., McCormick F., Shannon K.;\nRT   \"Biochemical characterization of a novel KRAS insertion mutation from\nRT   a human leukemia.\";\nRL   J. Biol. Chem. 271:32491-32494(1996).\nRN   [26]\nRP   VARIANTS GASC ASN-5; VAL-12; ASP-13 AND THR-59.\nRX   PubMed=14534542; DOI=10.1038/sj.onc.1206749;\nRA   Lee S.H., Lee J.W., Soung Y.H., Kim H.S., Park W.S., Kim S.Y.,\nRA   Lee J.H., Park J.Y., Cho Y.G., Kim C.J., Nam S.W., Kim S.H., Lee J.Y.,\nRA   Yoo N.J.;\nRT   \"BRAF and KRAS mutations in stomach cancer.\";\nRL   Oncogene 22:6942-6945(2003).\nRN   [27]\nRP   VARIANT PYLOCYTIC ASTROCYTOMA ARG-13.\nRX   PubMed=16247081; DOI=10.1212/01.wnl.0000180409.78098.d7;\nRA   Sharma M.K., Zehnbauer B.A., Watson M.A., Gutmann D.H.;\nRT   \"RAS pathway activation and an oncogenic RAS mutation in sporadic\nRT   pilocytic astrocytoma.\";\nRL   Neurology 65:1335-1336(2005).\nRN   [28]\nRP   VARIANTS NS3 GLY-152 (ISOSORM 2) AND VAL-153 (ISOFORM 2).\nRX   PubMed=16773572; DOI=10.1086/504394;\nRA   Carta C., Pantaleoni F., Bocchinfuso G., Stella L., Vasta I.,\nRA   Sarkozy A., Digilio C., Palleschi A., Pizzuti A., Grammatico P.,\nRA   Zampino G., Dallapiccola B., Gelb B.D., Tartaglia M.;\nRT   \"Germline missense mutations affecting KRAS Isoform B are associated\nRT   with a severe Noonan syndrome phenotype.\";\nRL   Am. J. Hum. Genet. 79:129-135(2006).\nRN   [29]\nRP   VARIANTS LUNG CARCINOMA CYS-12; ASP-12; SER-12; VAL-12 AND HIS-61.\nRX   PubMed=16533793; DOI=10.1158/1078-0432.CCR-05-1981;\nRA   Tam I.Y.S., Chung L.P., Suen W.S., Wang E., Wong M.C.M., Ho K.K.,\nRA   Lam W.K., Chiu S.W., Girard L., Minna J.D., Gazdar A.F., Wong M.P.;\nRT   \"Distinct epidermal growth factor receptor and KRAS mutation patterns\nRT   in non-small cell lung cancer patients with different tobacco exposure\nRT   and clinicopathologic features.\";\nRL   Clin. Cancer Res. 12:1647-1653(2006).\nRN   [30]\nRP   VARIANT CFC2 ARG-60.\nRX   PubMed=16474404; DOI=10.1038/ng1749;\nRA   Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A.,\nRA   Okamoto N., Hennekam R.C.M., Gillessen-Kaesbach G., Wieczorek D.,\nRA   Kavamura M.I., Kurosawa K., Ohashi H., Wilson L., Heron D.,\nRA   Bonneau D., Corona G., Kaname T., Naritomi K., Baumann C.,\nRA   Matsumoto N., Kato K., Kure S., Matsubara Y.;\nRT   \"Germline KRAS and BRAF mutations in cardio-facio-cutaneous\nRT   syndrome.\";\nRL   Nat. Genet. 38:294-296(2006).\nRN   [31]\nRP   VARIANTS NS3 ILE-14 AND ILE-58, VARIANT CFC2 ARG-34, AND\nRP   CHARACTERIZATION OF VARIANTS NS3 ILE-14 AND ILE-58.\nRX   PubMed=16474405; DOI=10.1038/ng1748;\nRA   Schubbert S., Zenker M., Rowe S.L., Boell S., Klein C., Bollag G.,\nRA   van der Burgt I., Musante L., Kalscheuer V., Wehner L.-E., Nguyen H.,\nRA   West B., Zhang K.Y.J., Sistermans E., Rauch A., Niemeyer C.M.,\nRA   Shannon K., Kratz C.P.;\nRT   \"Germline KRAS mutations cause Noonan syndrome.\";\nRL   Nat. Genet. 38:331-336(2006).\nRN   [32]\nRP   VARIANTS [LARGE SCALE ANALYSIS] ALA-12; ASP-12; SER-12; VAL-12;\nRP   ASP-13; ARG-61; ASN-117 AND THR-146.\nRX   PubMed=16959974; DOI=10.1126/science.1133427;\nRA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,\nRA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,\nRA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,\nRA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,\nRA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,\nRA   Vogelstein B., Kinzler K.W., Velculescu V.E.;\nRT   \"The consensus coding sequences of human breast and colorectal\nRT   cancers.\";\nRL   Science 314:268-274(2006).\nRN   [33]\nRP   VARIANT NS3 GLU-5.\nRX   PubMed=17468812; DOI=10.1007/s10038-007-0146-1;\nRA   Bertola D.R., Pereira A.C., Brasil A.S., Albano L.M., Kim C.A.,\nRA   Krieger J.E.;\nRT   \"Further evidence of genetic heterogeneity in Costello syndrome:\nRT   involvement of the KRAS gene.\";\nRL   J. Hum. Genet. 52:521-526(2007).\nRN   [34]\nRP   VARIANTS NS3 ILE-14; ARG-22; LEU-34; GLN-34; MET-36 AND VAL-153\nRP   (ISOFORM 2), VARIANT CFC2 GLU-22, VARIANT NS3/CFC2 ILE-156 (ISOFORM\nRP   2), AND VARIANTS ASN-5 AND LEU-156 (ISOFORM 2).\nRX   PubMed=17056636; DOI=10.1136/jmg.2006.046300;\nRA   Zenker M., Lehmann K., Schulz A.L., Barth H., Hansmann D., Koenig R.,\nRA   Korinthenberg R., Kreiss-Nachtsheim M., Meinecke P., Morlot S.,\nRA   Mundlos S., Quante A.S., Raskin S., Schnabel D., Wehner L.E.,\nRA   Kratz C.P., Horn D., Kutsche K.;\nRT   \"Expansion of the genotypic and phenotypic spectrum in patients with\nRT   KRAS germline mutations.\";\nRL   J. Med. Genet. 44:131-135(2007).\nRN   [35]\nRP   VARIANTS NS3 ILE-58 AND SER-60.\nRX   PubMed=19396835; DOI=10.1002/ajmg.a.32786;\nRA   Kratz C.P., Zampino G., Kriek M., Kant S.G., Leoni C., Pantaleoni F.,\nRA   Oudesluys-Murphy A.M., Di Rocco C., Kloska S.P., Tartaglia M.,\nRA   Zenker M.;\nRT   \"Craniosynostosis in patients with Noonan syndrome caused by germline\nRT   KRAS mutations.\";\nRL   Am. J. Med. Genet. A 149:1036-1040(2009).\nRN   [36]\nRP   CHARACTERIZATION OF VARIANTS NS3 ILE-14; ARG-22; LEU-34; ILE-58 AND\nRP   VAL-153 (ISOFORM 2), CHARACTERIZATION OF VARIANTS CFC2 GLU-22; ARG-34\nRP   AND ARG-60, AND CHARACTERIZATION OF VARIANTS ASN-5 AND LEU-156\nRP   (ISOFORM 2).\nRX   PubMed=20949621; DOI=10.1002/humu.21377;\nRA   Gremer L., Merbitz-Zahradnik T., Dvorsky R., Cirstea I.C., Kratz C.P.,\nRA   Zenker M., Wittinghofer A., Ahmadian M.R.;\nRT   \"Germline KRAS mutations cause aberrant biochemical and physical\nRT   properties leading to developmental disorders.\";\nRL   Hum. Mutat. 32:33-43(2011).\nRN   [37]\nRP   VARIANTS CFC2 HIS-71 AND GLU-147.\nRX   PubMed=21797849; DOI=10.1111/j.1399-0004.2011.01754.x;\nRA   Stark Z., Gillessen-Kaesbach G., Ryan M.M., Cirstea I.C., Gremer L.,\nRA   Ahmadian M.R., Savarirayan R., Zenker M.;\nRT   \"Two novel germline KRAS mutations: expanding the molecular and\nRT   clinical phenotype.\";\nRL   Clin. Genet. 81:590-594(2012).\nCC   -!- FUNCTION: Ras proteins bind GDP/GTP and possess intrinsic GTPase\nCC       activity.\nCC   -!- ENZYME REGULATION: Alternates between an inactive form bound to\nCC       GDP and an active form bound to GTP. Activated by a guanine\nCC       nucleotide-exchange factor (GEF) and inactivated by a GTPase-\nCC       activating protein (GAP).\nCC   -!- SUBUNIT: Interacts with PHLPP. Interacts (active GTP-bound form\nCC       preferentially) with RGS14 (By similarity).\nCC   -!- INTERACTION:\nCC       Q04631:Fnta (xeno); NbExp=2; IntAct=EBI-367427, EBI-602447;\nCC       P04049:RAF1; NbExp=2; IntAct=EBI-367427, EBI-365996;\nCC       P50749:RASSF2; NbExp=2; IntAct=EBI-367415, EBI-960081;\nCC   -!- SUBCELLULAR LOCATION: Cell membrane; Lipid-anchor; Cytoplasmic\nCC       side.\nCC   -!- ALTERNATIVE PRODUCTS:\nCC       Event=Alternative splicing; Named isoforms=2;\nCC         Comment=Isoforms differ in the C-terminal region which is\nCC         encoded by two alternative exons (IVA and IVB);\nCC       Name=2A; Synonyms=K-Ras4A;\nCC         IsoId=P01116-1; Sequence=Displayed;\nCC       Name=2B; Synonyms=K-Ras4B;\nCC         IsoId=P01116-2, P01118-1;\nCC         Sequence=VSP_011140, VSP_011141;\nCC         Note=Variant in position: 152:V->G (in NS3). Variant in\nCC         position: 153:D->V (in CFC2 and NS3, exhibits only minor\nCC         alterations in its in vitro biochemical behavior compared to\nCC         wild-type protein). Variant in position: 156:F->I (in NS3/CFC2).\nCC         Variant in position: 156:F->L (found in a patient with Costello\nCC         syndrome, exhibits an increase in intrinsic and guanine\nCC         nucleotide exchange factor catalyzed nucleotide exchange in\nCC         combination with an impaired GTPase-activating\nCC         protein-stimulated GTP hydrolysis but functional in interaction\nCC         with effectors);\nCC   -!- PTM: Acetylation at Lys-104 prevents interaction with guanine\nCC       nucleotide exchange factors (GEFs).\nCC   -!- DISEASE: Leukemia, acute myelogenous (AML) [MIM:601626]: A subtype\nCC       of acute leukemia, a cancer of the white blood cells. AML is a\nCC       malignant disease of bone marrow characterized by maturational\nCC       arrest of hematopoietic precursors at an early stage of\nCC       development. Clonal expansion of myeloid blasts occurs in bone\nCC       marrow, blood, and other tissue. Myelogenous leukemias develop\nCC       from changes in cells that normally produce neutrophils,\nCC       basophils, eosinophils and monocytes. Note=The disease is caused\nCC       by mutations affecting the gene represented in this entry.\nCC   -!- DISEASE: Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An\nCC       aggressive pediatric myelodysplastic syndrome/myeloproliferative\nCC       disorder characterized by malignant transformation in the\nCC       hematopoietic stem cell compartment with proliferation of\nCC       differentiated progeny. Patients have splenomegaly, enlarged lymph\nCC       nodes, rashes, and hemorrhages. Note=The disease is caused by\nCC       mutations affecting the gene represented in this entry.\nCC   -!- DISEASE: Noonan syndrome 3 (NS3) [MIM:609942]: A form of Noonan\nCC       syndrome, a disease characterized by short stature, facial\nCC       dysmorphic features such as hypertelorism, a downward eyeslant and\nCC       low-set posteriorly rotated ears, and a high incidence of\nCC       congenital heart defects and hypertrophic cardiomyopathy. Other\nCC       features can include a short neck with webbing or redundancy of\nCC       skin, deafness, motor delay, variable intellectual deficits,\nCC       multiple skeletal defects, cryptorchidism, and bleeding diathesis.\nCC       Individuals with Noonan syndrome are at risk of juvenile\nCC       myelomonocytic leukemia, a myeloproliferative disorder\nCC       characterized by excessive production of myelomonocytic cells.\nCC       Note=The disease is caused by mutations affecting the gene\nCC       represented in this entry.\nCC   -!- DISEASE: Gastric cancer (GASC) [MIM:613659]: A malignant disease\nCC       which starts in the stomach, can spread to the esophagus or the\nCC       small intestine, and can extend through the stomach wall to nearby\nCC       lymph nodes and organs. It also can metastasize to other parts of\nCC       the body. The term gastric cancer or gastric carcinoma refers to\nCC       adenocarcinoma of the stomach that accounts for most of all\nCC       gastric malignant tumors. Two main histologic types are\nCC       recognized, diffuse type and intestinal type carcinomas. Diffuse\nCC       tumors are poorly differentiated infiltrating lesions, resulting\nCC       in thickening of the stomach. In contrast, intestinal tumors are\nCC       usually exophytic, often ulcerating, and associated with\nCC       intestinal metaplasia of the stomach, most often observed in\nCC       sporadic disease. Note=The disease is caused by mutations\nCC       affecting the gene represented in this entry.\nCC   -!- DISEASE: Note=Defects in KRAS are a cause of pylocytic astrocytoma\nCC       (PA). Pylocytic astrocytomas are neoplasms of the brain and spinal\nCC       cord derived from glial cells which vary from histologically\nCC       benign forms to highly anaplastic and malignant tumors.\nCC   -!- DISEASE: Cardiofaciocutaneous syndrome 2 (CFC2) [MIM:615278]: A\nCC       form of cardiofaciocutaneous syndrome, a multiple congenital\nCC       anomaly disorder characterized by a distinctive facial appearance,\nCC       heart defects and mental retardation. Heart defects include\nCC       pulmonic stenosis, atrial septal defects and hypertrophic\nCC       cardiomyopathy. Some affected individuals present with ectodermal\nCC       abnormalities such as sparse, friable hair, hyperkeratotic skin\nCC       lesions and a generalized ichthyosis-like condition. Typical\nCC       facial features are similar to Noonan syndrome. They include high\nCC       forehead with bitemporal constriction, hypoplastic supraorbital\nCC       ridges, downslanting palpebral fissures, a depressed nasal bridge,\nCC       and posteriorly angulated ears with prominent helices. CFC2\nCC       patients often do not have the skin abnormalities, such as\nCC       ichthyosis, hyperkeratosis, and hemangioma observed in CFC1.\nCC       Note=The disease is caused by mutations affecting the gene\nCC       represented in this entry.\nCC   -!- DISEASE: Note=KRAS mutations are involved in cancer development.\nCC   -!- SIMILARITY: Belongs to the small GTPase superfamily. Ras family.\nCC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology\nCC       and Haematology;\nCC       URL=\"http://atlasgeneticsoncology.org/Genes/KRASID91.html\";\nCC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and\nCC       polymorphism database;\nCC       URL=\"http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=KRAS\";\nCC   -----------------------------------------------------------------------\nCC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms\nCC   Distributed under the Creative Commons Attribution-NoDerivs License\nCC   -----------------------------------------------------------------------\nDR   EMBL; L00049; AAB59444.1; -; Genomic_DNA.\nDR   EMBL; L00045; AAB59444.1; JOINED; Genomic_DNA.\nDR   EMBL; L00046; AAB59444.1; JOINED; Genomic_DNA.\nDR   EMBL; L00047; AAB59444.1; JOINED; Genomic_DNA.\nDR   EMBL; L00048; AAB59445.1; -; Genomic_DNA.\nDR   EMBL; L00045; AAB59445.1; JOINED; Genomic_DNA.\nDR   EMBL; L00046; AAB59445.1; JOINED; Genomic_DNA.\nDR   EMBL; L00047; AAB59445.1; JOINED; Genomic_DNA.\nDR   EMBL; M54968; AAB41942.1; -; mRNA.\nDR   EMBL; AF493917; AAM12631.1; -; mRNA.\nDR   EMBL; BT007153; AAP35817.1; -; mRNA.\nDR   EMBL; AK292510; BAF85199.1; -; mRNA.\nDR   EMBL; CH471094; EAW96511.1; -; Genomic_DNA.\nDR   EMBL; CH471094; EAW96512.1; -; Genomic_DNA.\nDR   EMBL; EU332849; ABY87538.1; -; Genomic_DNA.\nDR   EMBL; BC013572; AAH13572.1; -; mRNA.\nDR   EMBL; K01519; -; NOT_ANNOTATED_CDS; Genomic_DNA.\nDR   EMBL; K01520; -; NOT_ANNOTATED_CDS; Genomic_DNA.\nDR   EMBL; M25876; AAA35683.1; -; Genomic_DNA.\nDR   EMBL; M34904; AAA36149.1; -; Genomic_DNA.\nDR   EMBL; M30539; AAA36557.1; -; Genomic_DNA.\nDR   EMBL; X01669; CAA25828.1; -; Genomic_DNA.\nDR   EMBL; X02825; CAA26593.1; -; Genomic_DNA.\nDR   EMBL; K03210; AAA36554.1; -; Genomic_DNA.\nDR   EMBL; K03209; AAA36554.1; JOINED; Genomic_DNA.\nDR   CCDS; CCDS8702.1; -. [P01116-2]\nDR   CCDS; CCDS8703.1; -. [P01116-1]\nDR   PIR; A93311; TVHUK.\nDR   PIR; B93311; TVHU2K.\nDR   RefSeq; NP_004976.2; NM_004985.4. [P01116-2]\nDR   RefSeq; NP_203524.1; NM_033360.3. [P01116-1]\nDR   RefSeq; XP_006719132.1; XM_006719069.1. [P01116-1]\nDR   UniGene; Hs.37003; -.\nDR   UniGene; Hs.505033; -.\nDR   PDB; 1D8D; X-ray; 2.00 A; P=178-188.\nDR   PDB; 1D8E; X-ray; 3.00 A; P=178-188.\nDR   PDB; 1KZO; X-ray; 2.20 A; C=169-173.\nDR   PDB; 1KZP; X-ray; 2.10 A; C=169-173.\nDR   PDB; 3GFT; X-ray; 2.27 A; A/B/C/D/E/F=1-164.\nDR   PDB; 4DSN; X-ray; 2.03 A; A=2-164.\nDR   PDB; 4DSO; X-ray; 1.85 A; A=2-164.\nDR   PDB; 4EPR; X-ray; 2.00 A; A=1-164.\nDR   PDB; 4EPT; X-ray; 2.00 A; A=1-164.\nDR   PDB; 4EPV; X-ray; 1.35 A; A=1-164.\nDR   PDB; 4EPW; X-ray; 1.70 A; A=1-164.\nDR   PDB; 4EPX; X-ray; 1.76 A; A=1-164.\nDR   PDB; 4EPY; X-ray; 1.80 A; A=1-164.\nDR   PDB; 4L8G; X-ray; 1.52 A; A=1-169.\nDR   PDB; 4LPK; X-ray; 1.50 A; A/B=1-169.\nDR   PDB; 4LRW; X-ray; 2.15 A; A/B=1-169.\nDR   PDB; 4LUC; X-ray; 1.29 A; A/B=1-169.\nDR   PDB; 4LV6; X-ray; 1.50 A; A/B=1-169.\nDR   PDB; 4LYF; X-ray; 1.57 A; A/B/C=1-169.\nDR   PDB; 4LYH; X-ray; 1.37 A; A/B/C=1-169.\nDR   PDB; 4LYJ; X-ray; 1.93 A; A=1-169.\nDR   PDB; 4M1O; X-ray; 1.57 A; A/B/C=1-169.\nDR   PDB; 4M1S; X-ray; 1.55 A; A/B/C=1-169.\nDR   PDB; 4M1T; X-ray; 1.70 A; A/B/C=1-169.\nDR   PDB; 4M1W; X-ray; 1.58 A; A/B/C=1-169.\nDR   PDB; 4M1Y; X-ray; 1.49 A; A/B/C=1-169.\nDR   PDB; 4M21; X-ray; 1.94 A; A/B/C=1-169.\nDR   PDB; 4M22; X-ray; 2.09 A; A/B/C=1-169.\nDR   PDBsum; 1D8D; -.\nDR   PDBsum; 1D8E; -.\nDR   PDBsum; 1KZO; -.\nDR   PDBsum; 1KZP; -.\nDR   PDBsum; 3GFT; -.\nDR   PDBsum; 4DSN; -.\nDR   PDBsum; 4DSO; -.\nDR   PDBsum; 4EPR; -.\nDR   PDBsum; 4EPT; -.\nDR   PDBsum; 4EPV; -.\nDR   PDBsum; 4EPW; -.\nDR   PDBsum; 4EPX; -.\nDR   PDBsum; 4EPY; -.\nDR   PDBsum; 4L8G; -.\nDR   PDBsum; 4LPK; -.\nDR   PDBsum; 4LRW; -.\nDR   PDBsum; 4LUC; -.\nDR   PDBsum; 4LV6; -.\nDR   PDBsum; 4LYF; -.\nDR   PDBsum; 4LYH; -.\nDR   PDBsum; 4LYJ; -.\nDR   PDBsum; 4M1O; -.\nDR   PDBsum; 4M1S; -.\nDR   PDBsum; 4M1T; -.\nDR   PDBsum; 4M1W; -.\nDR   PDBsum; 4M1Y; -.\nDR   PDBsum; 4M21; -.\nDR   PDBsum; 4M22; -.\nDR   ProteinModelPortal; P01116; -.\nDR   SMR; P01116; 1-166.\nDR   BioGrid; 110043; 32.\nDR   DIP; DIP-33951N; -.\nDR   IntAct; P01116; 21.\nDR   MINT; MINT-131580; -.\nDR   STRING; 9606.ENSP00000256078; -.\nDR   ChEMBL; CHEMBL2189121; -.\nDR   PhosphoSite; P01116; -.\nDR   DMDM; 131875; -.\nDR   MaxQB; P01116; -.\nDR   PaxDb; P01116; -.\nDR   PeptideAtlas; P01116; -.\nDR   PRIDE; P01116; -.\nDR   DNASU; 3845; -.\nDR   Ensembl; ENST00000256078; ENSP00000256078; ENSG00000133703. [P01116-1]\nDR   Ensembl; ENST00000311936; ENSP00000308495; ENSG00000133703. [P01116-2]\nDR   GeneID; 3845; -.\nDR   KEGG; hsa:3845; -.\nDR   UCSC; uc001rgp.1; human. [P01116-1]\nDR   UCSC; uc001rgq.1; human. [P01116-2]\nDR   CTD; 3845; -.\nDR   GeneCards; GC12M025358; -.\nDR   GeneReviews; KRAS; -.\nDR   HGNC; HGNC:6407; KRAS.\nDR   MIM; 190070; gene.\nDR   MIM; 601626; phenotype.\nDR   MIM; 607785; phenotype.\nDR   MIM; 609942; phenotype.\nDR   MIM; 613659; phenotype.\nDR   MIM; 615278; phenotype.\nDR   neXtProt; NX_P01116; -.\nDR   Orphanet; 1340; Cardiofaciocutaneous syndrome.\nDR   Orphanet; 3071; Costello syndrome.\nDR   Orphanet; 1333; Familial pancreatic carcinoma.\nDR   Orphanet; 144; Hereditary nonpolyposis colon cancer.\nDR   Orphanet; 86834; Juvenile myelomonocytic leukemia.\nDR   Orphanet; 2612; Linear nevus sebaceus syndrome.\nDR   Orphanet; 648; Noonan syndrome.\nDR   Orphanet; 251612; Pilocytic astrocytoma.\nDR   Orphanet; 357194; Selection of therapeutic option in colorectal cancer.\nDR   Orphanet; 357191; Selection of therapeutic option in non-small cell lung carcinoma.\nDR   PharmGKB; PA30196; -.\nDR   eggNOG; COG1100; -.\nDR   HOGENOM; HOG000233973; -.\nDR   HOVERGEN; HBG009351; -.\nDR   InParanoid; P01116; -.\nDR   KO; K07827; -.\nDR   OMA; RRYNREM; -.\nDR   OrthoDB; EOG7QVM41; -.\nDR   PhylomeDB; P01116; -.\nDR   TreeFam; TF312796; -.\nDR   Reactome; REACT_111045; Developmental Biology.\nDR   Reactome; REACT_111102; Signal Transduction.\nDR   Reactome; REACT_116125; Disease.\nDR   Reactome; REACT_604; Hemostasis.\nDR   Reactome; REACT_6900; Immune System.\nDR   SignaLink; P01116; -.\nDR   ChiTaRS; KRAS; human.\nDR   EvolutionaryTrace; P01116; -.\nDR   GeneWiki; KRAS; -.\nDR   GenomeRNAi; 3845; -.\nDR   NextBio; 15131; -.\nDR   PRO; PR:P01116; -.\nDR   ArrayExpress; P01116; -.\nDR   Bgee; P01116; -.\nDR   CleanEx; HS_KRAS; -.\nDR   Genevestigator; P01116; -.\nDR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.\nDR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.\nDR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.\nDR   GO; GO:0019003; F:GDP binding; IEA:Ensembl.\nDR   GO; GO:0019002; F:GMP binding; IEA:Ensembl.\nDR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.\nDR   GO; GO:0005515; F:protein binding; IPI:IntAct.\nDR   GO; GO:0032403; F:protein complex binding; IDA:MGI.\nDR   GO; GO:0030036; P:actin cytoskeleton organization; IEA:Ensembl.\nDR   GO; GO:0000186; P:activation of MAPKK activity; TAS:Reactome.\nDR   GO; GO:0007411; P:axon guidance; TAS:Reactome.\nDR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.\nDR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl.\nDR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0006184; P:GTP catabolic process; IEA:InterPro.\nDR   GO; GO:0045087; P:innate immune response; TAS:Reactome.\nDR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.\nDR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.\nDR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.\nDR   GO; GO:0048011; P:neurotrophin TRK receptor signaling pathway; TAS:Reactome.\nDR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.\nDR   GO; GO:0010628; P:positive regulation of gene expression; IMP:BHF-UCL.\nDR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.\nDR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IEA:Ensembl.\nDR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IEA:Ensembl.\nDR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:BHF-UCL.\nDR   GO; GO:0035022; P:positive regulation of Rac protein signal transduction; IEA:Ensembl.\nDR   GO; GO:0007265; P:Ras protein signal transduction; TAS:Reactome.\nDR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.\nDR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl.\nDR   GO; GO:0051384; P:response to glucocorticoid; IEA:Ensembl.\nDR   GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl.\nDR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.\nDR   GO; GO:0035176; P:social behavior; IEA:Ensembl.\nDR   GO; GO:0051146; P:striated muscle cell differentiation; IEA:Ensembl.\nDR   GO; GO:0008542; P:visual learning; IEA:Ensembl.\nDR   Gene3D; 3.40.50.300; -; 1.\nDR   InterPro; IPR027417; P-loop_NTPase.\nDR   InterPro; IPR005225; Small_GTP-bd_dom.\nDR   InterPro; IPR001806; Small_GTPase.\nDR   InterPro; IPR020849; Small_GTPase_Ras.\nDR   PANTHER; PTHR24070; PTHR24070; 1.\nDR   Pfam; PF00071; Ras; 1.\nDR   PRINTS; PR00449; RASTRNSFRMNG.\nDR   SMART; SM00173; RAS; 1.\nDR   SUPFAM; SSF52540; SSF52540; 1.\nDR   TIGRFAMs; TIGR00231; small_GTP; 1.\nDR   PROSITE; PS51421; RAS; 1.\nPE   1: Evidence at protein level;\nKW   3D-structure; Acetylation; Alternative splicing; Cardiomyopathy;\nKW   Cell membrane; Complete proteome; Deafness; Direct protein sequencing;\nKW   Disease mutation; Ectodermal dysplasia; GTP-binding; Lipoprotein;\nKW   Membrane; Mental retardation; Methylation; Nucleotide-binding;\nKW   Palmitate; Polymorphism; Prenylation; Proto-oncogene;\nKW   Reference proteome.\nFT   CHAIN         1    186       GTPase KRas.\nFT                                /FTId=PRO_0000082641.\nFT   INIT_MET      1      1       Removed; alternate.\nFT   CHAIN         2    186       GTPase KRas, N-terminally processed.\nFT                                /FTId=PRO_0000326480.\nFT   PROPEP      187    189       Removed in mature form.\nFT                                /FTId=PRO_0000281291.\nFT   NP_BIND      10     17       GTP.\nFT   NP_BIND      57     61       GTP.\nFT   NP_BIND     116    119       GTP.\nFT   REGION      166    185       Hypervariable region.\nFT   MOTIF        32     40       Effector region.\nFT   MOD_RES       1      1       N-acetylmethionine; in GTPase KRas;\nFT                                alternate.\nFT   MOD_RES       2      2       N-acetylthreonine; in GTPase KRas, N-\nFT                                terminally processed.\nFT   MOD_RES     104    104       N6-acetyllysine.\nFT   MOD_RES     186    186       Cysteine methyl ester (By similarity).\nFT   LIPID       180    180       S-palmitoyl cysteine (By similarity).\nFT   LIPID       186    186       S-farnesyl cysteine (By similarity).\nFT   VAR_SEQ     151    153       RVE -> GVD (in isoform 2B).\nFT                                /FTId=VSP_011140.\nFT   VAR_SEQ     165    189       QYRLKKISKEEKTPGCVKIKKCIIM -> KHKEKMSKDGKK\nFT                                KKKKSKTKCVIM (in isoform 2B).\nFT                                /FTId=VSP_011141.\nFT   VARIANT       5      5       K -> E (in NS3).\nFT                                /FTId=VAR_065144.\nFT   VARIANT       5      5       K -> N (in GASC; found also in a patient\nFT                                with Costello syndrome; exhibits only\nFT                                minor alterations in its in vitro\nFT                                biochemical behavior compared to wild-\nFT                                type protein).\nFT                                /FTId=VAR_064849.\nFT   VARIANT      10     10       G -> GG (in one individual with AML;\nFT                                expression in 3T3 cell causes cellular\nFT                                transformation; expression in COS cells\nFT                                activates the Ras-MAPK signaling pathway;\nFT                                lower GTPase activity; faster GDP\nFT                                dissociation rate).\nFT                                /FTId=VAR_034601.\nFT   VARIANT      12     12       G -> A (in a colorectal cancer sample;\nFT                                somatic mutation).\nFT                                /FTId=VAR_036305.\nFT   VARIANT      12     12       G -> C (in lung carcinoma; somatic\nFT                                mutation).\nFT                                /FTId=VAR_006839.\nFT   VARIANT      12     12       G -> D (in pancreatic carcinoma, GASC and\nFT                                lung carcinoma; somatic mutation).\nFT                                /FTId=VAR_016026.\nFT   VARIANT      12     12       G -> R (in lung cancer and bladder\nFT                                cancer; somatic mutation).\nFT                                /FTId=VAR_016027.\nFT   VARIANT      12     12       G -> S (in lung carcinoma and GASC;\nFT                                somatic mutation).\nFT                                /FTId=VAR_016028.\nFT   VARIANT      12     12       G -> V (in lung carcinoma, pancreatic\nFT                                carcinoma, colon cancer and GASC; somatic\nFT                                mutation, constitutively activated).\nFT                                /FTId=VAR_006840.\nFT   VARIANT      13     13       G -> D (in a breast carcinoma cell line\nFT                                and GASC; somatic mutation).\nFT                                /FTId=VAR_016029.\nFT   VARIANT      13     13       G -> R (in pylocytic astrocytoma; somatic\nFT                                mutation; increase activation of the Ras\nFT                                pathway).\nFT                                /FTId=VAR_065145.\nFT   VARIANT      14     14       V -> I (in NS3; affects activity and\nFT                                impairs responsiveness to GTPase\nFT                                activating proteins; characterized by a\nFT                                strong increase of both intrinsic and\nFT                                guanine nucleotide exchanged factor-\nFT                                catalyzed nucleotide exchange leading to\nFT                                an increased level of the activated\nFT                                state).\nFT                                /FTId=VAR_026109.\nFT   VARIANT      22     22       Q -> E (in CFC2; exhibits an increase in\nFT                                intrinsic and guanine nucleotide exchange\nFT                                factor catalyzed nucleotide exchange in\nFT                                combination with an impaired GTPase-\nFT                                activating protein-stimulated GTP\nFT                                hydrolysis but functional in interaction\nFT                                with effectors).\nFT                                /FTId=VAR_064850.\nFT   VARIANT      22     22       Q -> R (in NS3; impairs GTPase-activating\nFT                                protein stimulated GTP hydrolysis with\nFT                                unaffected intrinsic functions and a\nFT                                virtually functional effector\nFT                                interaction).\nFT                                /FTId=VAR_064851.\nFT   VARIANT      34     34       P -> L (in NS3; characterized by a\nFT                                defective GTPase-activating protein\nFT                                sensitivity and a strongly reduced\nFT                                interaction with effectors).\nFT                                /FTId=VAR_064852.\nFT   VARIANT      34     34       P -> Q (in NS3).\nFT                                /FTId=VAR_064853.\nFT   VARIANT      34     34       P -> R (in CFC2; characterized by a\nFT                                defective GTPase-activating protein\nFT                                sensitivity and a strongly reduced\nFT                                interaction with effectors).\nFT                                /FTId=VAR_026110.\nFT   VARIANT      36     36       I -> M (in NS3).\nFT                                /FTId=VAR_064854.\nFT   VARIANT      58     58       T -> I (in NS3; affects activity and\nFT                                impairs responsiveness to GTPase\nFT                                activating proteins; exhibits only minor\nFT                                alterations in its in vitro biochemical\nFT                                behavior compared to wild-type protein).\nFT                                /FTId=VAR_026111.\nFT   VARIANT      59     59       A -> T (in bladder cancer and GASC;\nFT                                somatic mutation).\nFT                                /FTId=VAR_016030.\nFT   VARIANT      60     60       G -> R (in CFC2; characterized by a\nFT                                defective GTPase-activating protein\nFT                                sensitivity and a strongly reduced\nFT                                interaction with effectors).\nFT                                /FTId=VAR_026112.\nFT   VARIANT      60     60       G -> S (in NS3).\nFT                                /FTId=VAR_065146.\nFT   VARIANT      61     61       Q -> H (in lung carcinoma;\nFT                                dbSNP:rs17851045).\nFT                                /FTId=VAR_006841.\nFT   VARIANT      61     61       Q -> R (in a colorectal cancer sample;\nFT                                somatic mutation).\nFT                                /FTId=VAR_036306.\nFT   VARIANT      71     71       Y -> H (in CFC2).\nFT                                /FTId=VAR_069784.\nFT   VARIANT     117    117       K -> N (in a colorectal cancer sample;\nFT                                somatic mutation).\nFT                                /FTId=VAR_036307.\nFT   VARIANT     146    146       A -> T (in a colorectal cancer sample;\nFT                                somatic mutation).\nFT                                /FTId=VAR_036308.\nFT   VARIANT     147    147       K -> E (in CFC2).\nFT                                /FTId=VAR_069785.\nFT   MUTAGEN     164    164       R->A: Loss of GTP-binding activity.\nFT   STRAND        2     11\nFT   HELIX        16     25\nFT   STRAND       38     46\nFT   STRAND       49     57\nFT   HELIX        61     63\nFT   HELIX        66     74\nFT   STRAND       76     83\nFT   HELIX        87    103\nFT   TURN        104    106\nFT   STRAND      111    116\nFT   STRAND      120    122\nFT   HELIX       127    137\nFT   STRAND      141    143\nFT   TURN        146    148\nFT   HELIX       152    167\nSQ   SEQUENCE   189 AA;  21656 MW;  973547B2E11C2C81 CRC64;\n     MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG\n     QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL\n     PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC\n     VKIKKCIIM\n//\n"